Ads
related to: hypereosinophilic syndrome prevalence statistics definition- HES Treatment Option
Read About An Option To Treat HES
And Request A Representative Today.
- Identifying Patients
Discover What Your Peers Are Saying
About An HES Treatment Option.
- Clinical Study Info
Learn About The Clinical Study Info
Regarding An HES Treatment Option.
- Reimbursement Information
Help Get Your Patients Started With
An HES Treatment Today.
- HES Treatment Option
Search results
Results From The WOW.Com Content Network
Depending on eosinophil target-organ infiltration, the clinical presentation of hypereosinophilic syndrome (HES) varies from patient to patient. [13] Individuals with myeloproliferative variant HES may be more likely to experience mucosal ulcerations involving the genitalia or airways, while patients with lymphocytic variant HES typically exhibit prominent skin symptoms such as urticarial ...
The idiopathic hypereosinophilic syndrome is a disorder characterized by hypereosiophilia that is associated with eosinophil-based tissue or organ damage. While almost any organ or tissue may be damaged, the lung, skin, heart, blood vessels, sinuses, kidneys, and brain are the most commonly affected. [7]
Reslizumab, a newly developed antibody directed against interleukin 5 that has been successfully used to treat 4 patients with the hypereosinophilic syndrome, may also be of use for lymphocyte-variant eosinophilia. [4] [5] [10] [11] Patients suffering minimal or no disease complications have gone untreated. [4]
Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues.
The age-adjusted incidence of hypereosinophilic syndrome/chronic eosinophilic leukemia reported by the International Classification of Diseases for Oncology (Version 3) is ~0.036 per 100,000 with the mean frequency of FIP1L1-PDGFRA gene fusions occurring in ~10% of patients with hypereosinophilia as detected in developed countries. The fused ...
Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.
Signs and symptoms may include weight loss, fever, malaise, cough, skin and mucosal lesions, diarrhea, and peripheral neuropathy.Cardiac symptoms are also possible. [2]In cases associated with PDGFRB and FGFR1 mutations, splenomegaly is common.
Familial eosinophilia is a rare congenital disorder characterized by the presence of sustained elevations in blood eosinophil levels that reach ranges diagnostic of eosinophilia (i.e. 500–1500/microliter) or, far more commonly, hypereosinophilia (i.e. >1,500/microliter).